Amylyx Pharmaceuticals Inc. (AMLX)
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 27.40 -0.11%
AMLX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.44B
- EPS (TTM)
- -$1.41
- Dividend yield
- None
- 52-week range
- 10.83 – 41.14
- Day range
- 27.21 – 28.46
- Volume / Avg
- 2.06M / 2.33M
- Beta
- —
- Shares outstanding
- 125.51M
- Next earnings
- Nov 5, 2026
52-week range
AMLX stock today
Amylyx Pharmaceuticals (AMLX) closed at $27.43 on Oct 7, down 2.18% (-$0.61), versus the S&P 500's 0.22% decline. At this level, AMLX sits in the middle of its 52-week range of $10.83 to $41.14: 33.3% below the high, set on Aug 21, 2026 and 153.3% above the low. AMLX is up 127.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 103.3%.
Amylyx Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.41), so its P/E ratio is not meaningful. Amylyx Pharmaceuticals's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Amylyx Pharmaceuticals
Company profileAmylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joshua B. Cohen
- Headquarters
- Cambridge, MA
- Employees
- 136
- IPO year
- 2022
- Website
- amylyx.com
Financial highlights
Full financialsIn fiscal 2025, Amylyx Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Amylyx Pharmaceuticals reported a net loss of $144.7 million, compared with a loss of $301.7 million a year earlier. Diluted earnings per share came in at -$1.53.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $87.37M | $380.79M | $22.23M | $285.00K |
| Growth | -100.00% | -77.06% | +1612.94% | +7700.00% | — |
| Net income | $-144.74M | $-301.74M | $49.27M | $-198.38M | $-87.93M |
| EPS (diluted) | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-13.35 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$42.36+54.43%
- Strong buy 0
- Buy 11
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.38
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.39 vs —
Amylyx Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs AMLX |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs AMLX |
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs AMLX |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs AMLX |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs AMLX |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs AMLX |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs AMLX |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs AMLX |
Indexes, lists and sector
Amylyx Pharmaceuticals stock FAQ
What is Amylyx Pharmaceuticals's stock price today?
AMLX last traded at $27.43 as of Oct 7, 4:00 PM EDT, down 2.18% on the day. Prices are delayed at least 15 minutes.
When is Amylyx Pharmaceuticals's next earnings date?
Amylyx Pharmaceuticals is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.38.
Who is Amylyx Pharmaceuticals's CEO?
Mr. Joshua B. Cohen is the chief executive officer of Amylyx Pharmaceuticals Inc., which has about 136 employees.
What is the AMLX 52-week high?
The 52-week high for AMLX is $41.14 and the 52-week low is $10.83. The stock is currently 33.3% below its high.